Identification of Inflammatory Biomarkers in IgA Nephropathy Using the NanoString Technology: a Validation Study in Caucasians

Overview

Journal Inflamm Res

Specialties Allergy & Immunology
Pathology

Date 2024 Jan 30

PMID 38291238

Authors

Laurence Gaumond

Caroline Lamarche

Stephanie Beauchemin

Nathalie Henley

Naoual Elftouh

Casimiro Gerarduzzi

Louis-Philippe Laurin

Affiliations

Soon will be listed here.

Abstract

Objective And Design: Immunoglobulin A nephropathy (IgAN) is a kidney disease characterized by the accumulation of IgA deposits in the glomeruli of the kidney, leading to inflammation and damage to the kidney. The inflammatory markers involved in IgAN remain to be defined. Gene expression analysis platforms, such as the NanoString nCounter system, are promising screening and diagnostic tools, especially in oncology. Still, their role as a diagnostic and prognostic tool in IgAN remains scarce. In this study, we aimed to validate the use of NanoString technology to identify potential inflammatory biomarkers involved in the progression of IgAN.

Subjects: A total of 30 patients with biopsy-proven IgAN and 7 cases of antineutrophil cytoplasmic antibody (ANCA)-associated pauci-immune glomerulonephritis were included for gene expression measurement. For the immunofluorescence validation experiments, a total of 6 IgAN patients and 3 controls were included.

Methods: Total RNA was extracted from formalin-fixed paraffin-embedded kidney biopsy specimens, and a customized 48-plex human gene CodeSet was used to study 29 genes implicated in different biological pathways. Comparisons in gene expression were made between IgAN and ANCA-associated pauci-immune glomerulonephritis patients to delineate an expression profile specific to IgAN. Gene expression was compared between patients with low and moderate risk of progression. Genes for which RNA expression was associated with disease progression were analyzed for protein expression by immunofluorescence and compared with controls.

Results: IgAN patients had a distinct gene expression profile with decreased expression in genes IL-6, INFG, and C1QB compared to ANCA patients. C3 and TNFRSF1B were identified as potential biomarkers for IgAN progression in patients early in their disease course. Protein expression for those 2 candidate genes was upregulated in IgAN patients compared to controls. Expression of genes implicated in fibrosis (PTEN, CASPASE 3, TGM2, TGFB1, IL2, and TNFRSF1B) was more pronounced in IgAN patients with severe fibrosis compared to those with none.

Conclusions: Our findings validate our NanoString mRNA profiling by examining protein expression levels of two candidate genes, C3 and TNFRSF1B, in IgAN patients and controls. We also identified several upregulated mRNA transcripts implicated in the development of fibrosis that may be considered fibrotic markers within IgAN patients.

Citing Articles

Potential of SIRI and artificial intelligence in IgAN: bridging biomarkers and patient-centered care.

Nabi R, Zahid T, Farooqi H, Nabi Z Int Urol Nephrol. 2024; 57(2):675-676.

PMID: 39210234 DOI: 10.1007/s11255-024-04190-7.

References

Khalili M, Bonnefoy A, Genest D, Quadri J, Rioux J, Troyanov S . Clinical Use of Complement, Inflammation, and Fibrosis Biomarkers in Autoimmune Glomerulonephritis. Kidney Int Rep. 2020; 5(10):1690-1699. PMC: 7569694. DOI: 10.1016/j.ekir.2020.07.018. View

Kim I, Park Y, Song S, Seong E, Lee D, Bae S . Role of Akt1 in renal fibrosis and tubular dedifferentiation during the progression of acute kidney injury to chronic kidney disease. Korean J Intern Med. 2020; 36(4):962-974. PMC: 8273823. DOI: 10.3904/kjim.2020.198. View

Yang S, Chen B, Shi J, Chen F, Zhang J, Sun Z . Analysis of regulatory T cell subsets in the peripheral blood of immunoglobulin A nephropathy (IgAN) patients. Genet Mol Res. 2015; 14(4):14088-92. DOI: 10.4238/2015.October.29.28. View

Qing J, Li C, Hu X, Song W, Tirichen H, Yaigoub H . Differentiation of T Helper 17 Cells May Mediate the Abnormal Humoral Immunity in IgA Nephropathy and Inflammatory Bowel Disease Based on Shared Genetic Effects. Front Immunol. 2022; 13:916934. PMC: 9234173. DOI: 10.3389/fimmu.2022.916934. View

Haas M, Verhave J, Liu Z, Alpers C, Barratt J, Becker J . A Multicenter Study of the Predictive Value of Crescents in IgA Nephropathy. J Am Soc Nephrol. 2016; 28(2):691-701. PMC: 5280027. DOI: 10.1681/ASN.2016040433. View

Li G, Wu W, Zhang X, Huang Y, Wen Y, Li X . Serum levels of tumor necrosis factor alpha in patients with IgA nephropathy are closely associated with disease severity. BMC Nephrol. 2018; 19(1):326. PMC: 6236996. DOI: 10.1186/s12882-018-1069-0. View

Sonoda Y, Gohda T, Suzuki Y, Omote K, Ishizaka M, Matsuoka J . Circulating TNF receptors 1 and 2 are associated with the severity of renal interstitial fibrosis in IgA nephropathy. PLoS One. 2015; 10(4):e0122212. PMC: 4393287. DOI: 10.1371/journal.pone.0122212. View

Levey A, Stevens L, Schmid C, Zhang Y, Castro 3rd A, Feldman H . A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009; 150(9):604-12. PMC: 2763564. DOI: 10.7326/0003-4819-150-9-200905050-00006. View

Mendelson M, Johannes R, Liu C, Huan T, Yao C, Miao X . Epigenome-Wide Association Study of Soluble Tumor Necrosis Factor Receptor 2 Levels in the Framingham Heart Study. Front Pharmacol. 2018; 9:207. PMC: 5928448. DOI: 10.3389/fphar.2018.00207. View

10.

Wyatt R, Julian B . IgA nephropathy. N Engl J Med. 2013; 368(25):2402-14. DOI: 10.1056/NEJMra1206793. View

11.

Huang H, Peng Y, Long X, Liu Z, Wen X, Jia M . Tonsillar CD4+CD25+ regulatory T cells from IgA nephropathy patients have decreased immunosuppressive activity in experimental IgA nephropathy rats. Am J Nephrol. 2013; 37(5):472-80. DOI: 10.1159/000350533. View

12.

Lan A, Du J . Potential role of Akt signaling in chronic kidney disease. Nephrol Dial Transplant. 2014; 30(3):385-94. DOI: 10.1093/ndt/gfu196. View

13.

Chen K, Hsu H, Yang H, Tian Y, Ko Y, Yang C . Inhibition of spleen tyrosine kinase (syk) suppresses renal fibrosis through anti-inflammatory effects and down regulation of the MAPK-p38 pathway. Int J Biochem Cell Biol. 2016; 74:135-44. DOI: 10.1016/j.biocel.2016.03.001. View

14.

Chen H, Kleinberger J, Takane K, Salim F, Fiaschi-Taesch N, Pappas K . Augmented Stat5 Signaling Bypasses Multiple Impediments to Lactogen-Mediated Proliferation in Human β-Cells. Diabetes. 2015; 64(11):3784-97. PMC: 4613973. DOI: 10.2337/db15-0083. View

15.

Jin L, Ye H, Xu X, Zheng Y, Chen Y . MiR-133a/133b inhibits Treg differentiation in IgA nephropathy through targeting FOXP3. Biomed Pharmacother. 2018; 101:195-200. DOI: 10.1016/j.biopha.2018.02.022. View

16.

Oh Y, An J, Kim C, Yang S, Lee H, Kim D . Circulating Tumor Necrosis Factor α Receptors Predict the Outcomes of Human IgA Nephropathy: A Prospective Cohort Study. PLoS One. 2015; 10(7):e0132826. PMC: 4503615. DOI: 10.1371/journal.pone.0132826. View

17.

Miedziaszczyk M, Oko A, Wolc A, Wozniak A, Idasiak-Piechocka I . Assessment of serum concentration and urinary excretion of tumor necrosis factor receptor 1 and 2 and their potential as markers of immunoglobulin A nephropathy activity. Adv Clin Exp Med. 2023; 33(6):583-591. DOI: 10.17219/acem/171000. View

18.

Pattrapornpisut P, Avila-Casado C, Reich H . IgA Nephropathy: Core Curriculum 2021. Am J Kidney Dis. 2021; 78(3):429-441. DOI: 10.1053/j.ajkd.2021.01.024. View

19.

Duffield J . Cellular and molecular mechanisms in kidney fibrosis. J Clin Invest. 2014; 124(6):2299-306. PMC: 4038570. DOI: 10.1172/JCI72267. View

20.

Lin F, Jiang G, Shan J, Zhu C, Zou J, Wu X . Imbalance of regulatory T cells to Th17 cells in IgA nephropathy. Scand J Clin Lab Invest. 2012; 72(3):221-9. DOI: 10.3109/00365513.2011.652158. View